D
Deleted2797112
.
Last edited by a moderator:
- Joined
- 31 May 2016
- Messages
- 25,165
- Reaction score
- 5,529
- Country
I'm talking about the roll-out not the trial. The trial will be 0.5-1% (that's pretty much the industry norm for new vaccines), though so far there haven't been many. The roll-out will target the most at risk. Adverse events tend to be much more common in older people.
I suspect you could find one (source) in various academic studies by googling "vaccine adverse events". My source is a mate of mate shall we say.
I suspect you could find one (source) in various academic studies by googling "vaccine adverse events". My source is a mate of mate shall we say.
Different vaccines are used in different ways. It's not unheard of for those that'd be most effected by a disease to be protected by vaccinating everyone else, because the disease and the vaccine are both too dangerous for the at risk people.
All vaccines represent a risk/reward balance. That's what Stage 3 and 4 testing is for, to see if the risk/reward ratio is right for the vaccines in question.
All vaccines represent a risk/reward balance. That's what Stage 3 and 4 testing is for, to see if the risk/reward ratio is right for the vaccines in question.
Similar threads
- Locked
